Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study

NCT02677298 is registered in ClinicalTrials.gov with Croma-Pharma GmbH as lead sponsor.

NCT NCT02677298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02677298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study
Lead sponsor
Croma-Pharma GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 2, 2016
Completion date
November 16, 2017
Enrollment
784 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines